Patents by Inventor John L. Zenk

John L. Zenk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NANOPARTICLE ISOFLAVONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20220370403
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: February 10, 2022
    Publication date: November 24, 2022
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20210000788
    Abstract: The present invention is directed to formulations of genistein and methods for making and using, the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: July 21, 2020
    Publication date: January 7, 2021
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Nanoparticle isoflavone compositions and methods of making and using the same
    Patent number: 10729674
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: August 4, 2020
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20190160038
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: July 3, 2018
    Publication date: May 30, 2019
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Method of mitigating long and short term detrimental effects of exposure to low dose ionizing radiation by administration of genistein
    Patent number: 10220018
    Abstract: Mitigation of long and short-term detrimental effects of exposure to low dose ionizing radiation by administration of genistein in the form of a nanosuspension to a mammal in an amount effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to the ionizing radiation to twelve hours after exposure to the ionizing radiation.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: March 5, 2019
    Assignee: Humanetics Corporation
    Inventors: Michael D. Kaytor, John L. Zenk
  • Method of Mitigating Long and Short Term Detrimental Effects of Exposure to Low Dose Ionizing Radiation by Administration of Genistein
    Publication number: 20180256535
    Abstract: Mitigation of long and short-term detrimental effects of exposure to low dose ionizing radiation by administration of genistein in the form of a nanosuspension to a mammal in an amount effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to the ionizing radiation to twelve hours after exposure to the ionizing radiation.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Inventors: Michael D. Kaytor, John L. Zenk
  • Nanoparticle isoflavone compositions and methods of making and using the same
    Patent number: 10039739
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: August 7, 2018
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Method of mitigating long term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
    Patent number: 9993455
    Abstract: Mitigation of long term detrimental effects of exposure to medical imaging ionizing radiation by administration of an amount of genistein in the form of a nanosuspension to someone effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to medical imaging ionizing radiation to twelve hours after exposure to medical imaging ionizing radiation.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: June 12, 2018
    Assignee: Humanetics Corporation
    Inventors: Michael D. Kaytor, John L. Zenk
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20170304258
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 26, 2017
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Nanoparticle isoflavone compositions and methods of making and using the same
    Patent number: 9724325
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: August 8, 2017
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • METHOD OF MITIGATING LONG TERM DETRIMENTAL EFFECTS OF EXPOSURE TO MEDICAL IMAGING IONIZING RADIATION BY ADMINISTRATION OF GENISTEIN
    Publication number: 20170172976
    Abstract: Mitigation of long term detrimental effects of exposure to medical imaging ionizing radiation by administration of an amount of genistein in the form of a nano suspension to someone effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to medical imaging ionizing radiation to twelve hours after exposure to medical imaging ionizing radiation.
    Type: Application
    Filed: March 6, 2017
    Publication date: June 22, 2017
    Inventors: Michael D. Kaytor, John L. Zenk
  • Nanoparticle isoflavone compositions and methods of making and using the same
    Patent number: 9636322
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: May 2, 2017
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy
    Patent number: 9623004
    Abstract: A method for mitigating erectile dysfunction as an adverse side effect of radiation therapy for prostate cancer, comprising administration of a therapeutic dosage of genistein to a patient diagnosed with prostate cancer throughout only a primary administration period that commences a defined period of up to two weeks prior to commencement of radiation therapy for prostate cancer and extends beyond conclusion of the radiation therapy.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: April 18, 2017
    Inventors: Michael D. Kaytor, John L. Zenk, Geoffrey E. Schroeder, Zeljko Vujaskovic, Isabel Lauren Jackson
  • Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
    Patent number: 9623003
    Abstract: Mitigation of long and short-term detrimental effects of exposure to medical imaging ionizing radiation by administration of an effective amount of genistein in the form of a nanosuspension to someone within forty eight hours prior to and/or within twelve hours after exposure to medical imaging ionizing radiation.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: April 18, 2017
    Assignee: Humanetics Corporation
    Inventors: Michael D. Kaytor, John L. Zenk
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20160374984
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: September 7, 2016
    Publication date: December 29, 2016
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20160175276
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: March 1, 2016
    Publication date: June 23, 2016
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Nanoparticle isoflavone compositions and methods of making and using the same
    Patent number: 9308167
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: April 12, 2016
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • GENISTEIN CANCER TREATMENT REGIMEN MAXIMIZING CANCER RADIATION THERAPY BENEFITS
    Publication number: 20150126597
    Abstract: A treatment regimen for a patient undergoing fractionated radiation therapy for a solid tumor type cancer to attain an improvement in one or more of and an optimized balancing of cancer cell radiation sensitization, normal cell radioprotection, selective post-exposure inhibition of cancer cell recovery relative to normal cell recovery, and stabilization of body weight during radiation treatment. The regimen comprises administration of a therapeutic amount of genistein to a patient diagnosed with a solid tumor type cancer throughout an administration period that commences at least five days prior to commencement of fractionated cancer radiation therapy and extends until at least the conclusion of fractionated cancer radiation therapy.
    Type: Application
    Filed: November 7, 2013
    Publication date: May 7, 2015
    Inventors: Michael D. Kaytor, John L. Zenk
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20150050357
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 19, 2015
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • ADMINISTRATION OF A THERAPEUTIC AMOUNT OF GENISTEIN TO MITIGATE ERECTILE DYSFUNCTION RESULTING FROM RADIATION THERAPY FOR PROSTATE CANCER ONLY THROUGHOUT A DEFINED ADMINISTRATION PERIOD COMMENCING SHORTLY BEFORE AND CONCLUDING AFTER RADIATION THERAPY
    Publication number: 20150038572
    Abstract: A method for mitigating erectile dysfunction as an adverse side effect of radiation therapy for prostate cancer, comprising administration of a therapeutic dosage of genistein to a patient diagnosed with prostate cancer throughout only a primary administration period that commences a defined period of up to two weeks prior to commencement of radiation therapy for prostate cancer and extends beyond conclusion of the radiation therapy.
    Type: Application
    Filed: July 30, 2014
    Publication date: February 5, 2015
    Inventors: Michael D. Kaytor, John L. Zenk, Geoffrey E. Schroeder